These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35335053)

  • 1. Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis.
    Gao P; Cai S; Liu Q; Du M; Liu J; Liu M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis.
    Gao P; Kang LY; Liu J; Liu M
    World J Pediatr; 2023 Nov; 19(11):1041-1054. PubMed ID: 36723827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis.
    Lan Z; Yan J; Yang Y; Tang Z; Guo X; Wu Z; Jin Q
    Eur J Pediatr; 2023 Dec; 182(12):5235-5244. PubMed ID: 37768334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis.
    Watanabe A; Kani R; Iwagami M; Takagi H; Yasuhara J; Kuno T
    JAMA Pediatr; 2023 Apr; 177(4):384-394. PubMed ID: 36689319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis.
    Lu W; Zeng S; Yao Y; Luo Y; Ruan T
    Front Public Health; 2024; 12():1338208. PubMed ID: 38660347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
    Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study.
    Kildegaard H; Lund LC; Højlund M; Stensballe LG; Pottegård A
    BMJ; 2022 Apr; 377():e068898. PubMed ID: 35410884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
    Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
    BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials.
    Yang ZR; Jiang YW; Li FX; Liu D; Lin TF; Zhao ZY; Wei C; Jin QY; Li XM; Jia YX; Zhu FC; Yang ZY; Sha F; Feng ZJ; Tang JL
    Lancet Microbe; 2023 Apr; 4(4):e236-e246. PubMed ID: 36868258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis.
    Rahman MO; Kamigaki T; Thandar MM; Haruyama R; Yan F; Shibamura-Fujiogi M; Khin Maung Soe J; Islam MR; Yoneoka D; Miyahara R; Ota E; Suzuki M
    BMJ Open; 2023 Dec; 13(12):e076892. PubMed ID: 38128943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
    Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
    Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions to increase COVID-19 vaccine uptake: a scoping review.
    Andreas M; Iannizzi C; Bohndorf E; Monsef I; Piechotta V; Meerpohl JJ; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015270. PubMed ID: 35920693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.
    Deng J; Ma Y; Liu Q; Du M; Liu M; Liu J
    Int J Environ Res Public Health; 2022 Aug; 19(17):. PubMed ID: 36078466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study.
    Lang AL; Hohmuth N; Višković V; Konigorski S; Scholz S; Balzer F; Remschmidt C; Leistner R
    J Med Internet Res; 2024 Jun; 26():e47070. PubMed ID: 38833299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of COVID-19 vaccines.
    Graña C; Ghosn L; Evrenoglou T; Jarde A; Minozzi S; Bergman H; Buckley BS; Probyn K; Villanueva G; Henschke N; Bonnet H; Assi R; Menon S; Marti M; Devane D; Mallon P; Lelievre JD; Askie LM; Kredo T; Ferrand G; Davidson M; Riveros C; Tovey D; Meerpohl JJ; Grasselli G; Rada G; Hróbjartsson A; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD015477. PubMed ID: 36473651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
    Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.